425: Adagio Medical Announces European Commercial Launch and FDA Pivotal IDE Approval for Ventricular Tachycardia Cryoablation System

Adagio Medical announces the first European commercial procedures using its VT Cryoablation System and FDA approval for its FULCRUM-VT Pivotal IDE study.

Summary

• Adagio Medical has completed the first commercial procedures in Europe using its CE-Marked Ventricular Tachycardia (VT) Cryoablation System.
• The company has also received FDA approval in the U.S. for the FULCRUM-VT Pivotal IDE study of the VT Cryoablation System.
• The VT Cryoablation System uses Adagio's ultra-low cryoablation technology (ULTC) and is designed to improve the efficiency of VT ablations.
• The FULCRUM-VT study will enroll 206 patients with monomorphic VT at 20 U.S. and Canadian centers.
• Initial data from the FULCRUM-VT Early Feasibility (EFS IDE) study is expected to be presented on May 19, 2024.
• The company believes it has strong momentum in both commercial launch and clinical trials.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the CE Mark approval, FDA study approval, and positive comments from medical professionals. However, the forward-looking statements and potential funding gap introduce some uncertainty.

Positives

• CE Mark approval allows for commercial use of the VT Cryoablation System in Europe.
• FDA approval of the FULCRUM-VT Pivotal IDE study enables further clinical evaluation in the U.S.
• The ULTC technology offers potential improvements in the efficiency and effectiveness of VT ablations.
• The Cryocure-VT study demonstrated the safety and effectiveness of the technology.
• The company anticipates strong interest in study participation from top academic electrophysiology programs.

Risks

• Forward-looking statements are subject to risks, uncertainties, and other factors that may cause actual results to differ materially.
• The safety and effectiveness of the technology demonstrated in the Cryocure-VT study needs to be confirmed in the post-market setting.
• The company's expected cash runway extends through 2025, but there is a funding gap that needs to be addressed.

Future Outlook

Adagio Medical anticipates sharing progress on both commercial launch and clinical trials program fronts and expects a lot of interest in study participation from the top academic electrophysiology programs in the U.S.

Management Comments

• Professor Dr. Roland Tilz stated that the size and depth of lesions achievable using ULTC technology and catheter design makes it a game changer in time consuming large area ablations.
• Dr. Atul Verma recognized the value of ULTC technology in VT ablation procedures.
• Olav Bergheim, President and CEO of Adagio, stated that the company has strong momentum in both commercial launch and clinical trials program.

Industry Context

The announcement addresses the unmet need for innovation in VT ablation, a field where procedures are highly technical, time-consuming, and carry a risk of complications, with the majority of procedures performed in high-volume academic centers.

Comparison to Industry Standards

• The document references the Cryocure-VT study, which provides a benchmark for the safety and effectiveness of ultra-low-temperature cryoablation compared to conventional radiofrequency (RF) ablations.
• The document references EHRA survey results regarding management of ventricular tachycardias.
• The document references a J Am Coll Cardiol EP article regarding Ventricular Tachycardia Ablation: Past, Present, and Future Perspectives.

Stakeholder Impact

• Shareholders: Potential for increased value due to commercialization and clinical trial progress.
• Patients: Access to a potentially more effective and efficient treatment for ventricular tachycardia.
• Electrophysiologists: Opportunity to participate in clinical trials and utilize innovative technology.
• Hospitals: Potential to offer advanced VT ablation procedures.

Next Steps

• Enrollment of 206 patients in the FULCRUM-VT Pivotal IDE study at 20 U.S. and Canadian centers.
• Presentation of initial data from the FULCRUM-VT Early Feasibility (EFS IDE) study at the Heart Rhythm Society Meeting on May 19, 2024.
• Continued commercial launch of the VT Cryoablation System in Europe.
• Further development and expansion of the proprietary ULTC platform.

Key Dates